These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. Van Leusden HA, Albertyn G, Verlaine C, Van Ruymbeke J. Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679 [Abstract] [Full Text] [Related]
3. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Rozenberg S, Ylikorkala O, Arrenbrecht S. Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385 [Abstract] [Full Text] [Related]
4. [Transdermal administration of estrogens in women with the postcastration and climacteric syndromes]. Rotta L, Matĕchová E. Cesk Gynekol; 1992 Sep; 57(7):336-40. PubMed ID: 1394497 [Abstract] [Full Text] [Related]
5. [Systen--transdermal estradiol for substitution following surgical menopause]. Rachev E, Karag'ozov I. Akush Ginekol (Sofiia); 1995 Sep; 34(3):74-6. PubMed ID: 8743861 [Abstract] [Full Text] [Related]
6. Use of transdermal oestradiol (Estraderm TTS) in hypertensive postmenopausal women. Foidart JM. Br J Clin Pract Suppl; 1996 Sep; 86():14-6. PubMed ID: 8995005 [No Abstract] [Full Text] [Related]
7. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group. al-Azzawi F, Van der Mooren MJ, Rolland R, Hirvonen E. Br J Clin Pract; 1997 Sep; 51(1):20-3, 25-6. PubMed ID: 9158267 [Abstract] [Full Text] [Related]
12. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Maffei S, Del Ry S, Prontera C, Clerico A. Clin Sci (Lond); 2001 Nov; 101(5):447-53. PubMed ID: 11672449 [Abstract] [Full Text] [Related]
13. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Diem S, Grady D, Quan J, Vittinghoff E, Wallace R, Hanes V, Ensrud K. Menopause; 2006 Nov; 13(1):130-8. PubMed ID: 16607109 [Abstract] [Full Text] [Related]
14. [Oral or transdermal estrogen substitution therapy in climacteric?]. Runnebaum B, Salbach B, von Holst T. Geburtshilfe Frauenheilkd; 1994 Mar; 54(3):119-30. PubMed ID: 8188009 [Abstract] [Full Text] [Related]
15. Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Ettinger B, Pressman A. Am J Manag Care; 1999 Jun; 5(6):779-85. PubMed ID: 10538456 [Abstract] [Full Text] [Related]
16. [Splenopeptides for climacteric complaints. Comparison of ovarian stimulation with transdermal estradiol substitution]. Lauritzen C, Teucher T, Schmitz H. Arzneimittelforschung; 1995 Mar; 45(3):315-22. PubMed ID: 7741793 [Abstract] [Full Text] [Related]
17. [Kliogest--the possibility of hormonal substitution in the postmenopause]. Rachev E. Akush Ginekol (Sofiia); 1993 Mar; 32(3):64-6. PubMed ID: 8037328 [Abstract] [Full Text] [Related]
18. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int J Fertil Menopausal Stud; 1993 Mar; 38(1):5-11. PubMed ID: 8485612 [Abstract] [Full Text] [Related]